J1146: Efficacy and Safety of Oral Kanglaite (KLTc) Gelcap in Men with Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc Gelcaps (3 or 6 capsules four times/day) on Prostate Specific Antigen (PSA) Doubling Time Among Men with Rising PSA Levels after Definitive Local Therapy for Prostate Cancer
The primary purpose of this study is to evaluate the effects and safety of two different doses (3 or 6 capsules, four times daily) of KANGLAITE on prostate cancer in men who have rising PSA after initial local therapy.  A trial in patients with prostate cancer is proposed because of anecdotal reports of rapid declines in serum PSA associated with KLTc administration in the US and in China.
Website: http://clinicaltrials.gov/ct2/show/NCT01483586?term=kanglaite&rank=1
Principal Investigator:  Jason Taksey, M.D. (410) 573-5300
Research Staff:  Elizabeth Egan, RN (443) 481-5811
                               Steven DeMartino, CCRC, CRT, RPFT, AEC (443) 481-4390

R0534: SPPORT: A Phase III Trial of Short term Androgen Deprivation with Pelvic Lymph Node or Prostate bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
The purpose of this clinical trial is to study prostate radiation therapy. A steroid hormone called Androgen can cause the grown of prostate cancer cells. The purpose of this study is to determine how well prostate radiation therapy alone works compared to short –term androgen deprivation therapy given together with pelvic lymph node radiation therapy, either with or without prostate radiation therapy. This study is used in treating patients with a rising PSA after surgery for prostate cancer.
Website: link
Principal Investigator: Dr. Angel Torano – (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. – (443)481-5811

R0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
The purpose of this study is to compare radiation therapy to androgen-deprivation therapy. Androgen-deprivation therapy may lessen the amount of androgens made by the body, which can cause the growth of prostate cancer cells. It is unknown how affective radiation therapy alone is compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
Website: http://clinicaltrials.gov/ct2/show/NCT00936390?term=A+Phase+III+Prospective+Randomized+Trial+of+Dose-Escalated+Radiotherapy&rank=1
Principal Investigator: Dr. Angel Torano – (443)481-5800
Research Coordinator: Elizabeth Egan, R.N. – (443)481-5811

E7080-G000-205: An open-label, multicenter Phase 1b/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment
The main purpose of this study is to look at the effects (good and/or bad) of E7080 alone or in combination with everolimus on patients and your renal cell cancer and to compare this with everolimus on its own. http://clinicaltrials.gov/ct2/results?term=RENAL+CANCER++E7080&recr=&rslt=&type=&cond=&intr=&outc=&spons=&lead=& Principal Investigator:  Dr. Peter Graze, MD. (443)-573-5300
Research Staff:  Steven DeMartino, CCRC, CRT, RPFT, AEC (443)-481-4390